Human Immunology News Volume 9.13 | Apr 6 2021

    0
    25






    HIN 9.13 | Apr 6 2021


    Human Immunology News by STEMCELL Technologies
    Vol. 9.13 – 6 April, 2021
    TOP STORY

    Clearance of Pegylated Interferon by Kupffer Cells Limits NK Cell Activation and Therapy Response of Patients with HBV Infection

    Scientists found that patients with early natural killer cell activation after PEG–IFN-α injection experienced greater liver inflammation, lysis of HBV-infected hepatocytes, and hepatitis B surface antigen decline than those without.
    [Science Translational Medicine]

    Abstract

    The Immunology Podcast is here. Find it wherever you get your podcasts.
    PUBLICATIONSRanked by the impact factor of the journal

    Human Plasmacytoid Dendritic Cells Mount a Distinct Antiviral Response to Virus-Infected Cells

    Human plasmacytoid dendritic cells produced high amounts of type I interferon when incubated with live cytomegalovirus-infected fibroblasts but not with free cytomegalovirus
    [Science Immunology]

    Abstract

    Type I Interferons Affect the Metabolic Fitness of CD8+ T Cells from Patients with Systemic Lupus Erythematosus

    Investigators showed downregulation of mitochondria-derived genes and mitochondria-associated metabolic pathways in IFN-High patients from transcriptomic analysis of CD4+ and CD8+ T cells.
    [Nature Communications]

    Full Article

    A Slowly Cleaved Viral Signal Peptide Acts as a Protein-Integral Immune Evasion Domain

    Researchers showed that the N-terminal signal peptide was the major US9 functional domain targeting MICA*008 to proteasomal degradation.
    [Nature Communications]

    Full Article

    Hematopoietic Stem Progenitor Cells Lacking HLA Differ from Those Lacking GPI-Anchored Proteins in the Hierarchical Stage and Sensitivity to Immune Attack in Patients with Acquired Aplastic Anemia

    To characterize glycosylphosphatidylinositol-anchored protein-deficient and HLA-class I allele-lacking hematopoietic stem progenitor cells in acquired aplastic anemia (AA), researchers studied the peripheral blood of 56 AA patients in remission.
    [Leukemia]

    Abstract

    RNA-Sequencing Data-Driven Dissection of Human Plasma Cell Differentiation Reveals New Potential Transcription Regulators

    The authors present a comprehensive, temporal program of gene expression data encompassing human plasma cell differentiation using RNA sequencing
    [Leukemia]

    Full Article

    Inositol 1,4, 5-Trisphosphate 3-Kinase B Promotes Ca2+ Mobilization and the Inflammatory Activity of Dendritic Cells

    Researchers showed that the IP3 receptor 3 and ITPKB, a kinase that converts IP3 to inositol 1,3,4,5-tetrakisphosphate, were both necessary for Ca2+ mobilization and NFAT activation in mouse and human dendritic cells.
    [Science Signaling]

    Abstract

    Development of a Bispecific Immune Engager Using a Recombinant Malaria Protein

    Scientists used a protein conjugation system to produce a bispecific immune engager, V-aCD3, based on recombinant VAR2CSA as the cancer targeting moiety and an anti-CD3 single-chain variable fragment linked to a single-chain Fc as the immune engager.
    [Cell Death & Disease]

    Full Article

    Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity against CD80/CD86–Positive B Cell Malignancies

    CTLA4-chimeric antigen receptor T cells were found to accumulate in tumors and are toxic to myeloid-derived suppressor cells without signs of severe graft-versus-host disease and cytokine release syndrome in preclinical models.
    [Frontiers in Immunology]

    Full Article

    Explore scientific events this April with the Science Events Calendar.
    REVIEWS

    Cellular and Molecular Mechanisms Breaking Immune Tolerance in Inborn Errors of Immunity

    Scientists demonstrated that ZIP8 was specifically upregulated in CD4+ T cells that infiltrated the inflamed joint and that ZIP8 deficiency in CD4+ T cells abrogated collagen-induced arthritis.
    [Experimental & Molecular Medicine]

    Full Article

    INDUSTRY AND POLICY NEWS

    Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics

    Sorrento Therapeutics, Inc. announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058, preclinical stage candidate AC0939, and ACEA’s extensive proprietary library of small molecules, which potentially have applications for numerous human disease indications.
    [Sorrento Therapeutics, Inc. (Globe Newswire, Inc.)]

    Press Release

    Kite Submits Supplemental Biologics License Application to US Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

    Kite announced that it has submitted a supplemental Biologics License Application to FDA for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    [Kite (BusinessWire, Inc.)]

    Press Release

    FEATURED EVENT

    Wisconsin Stem Cell Symposium: The Single Cell Revolution in Stem Cells

    April 14, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Faculty Position – Brain Immunology and Glia

    University of Virginia – Charlottesville, Virginia, United States

    Postdoctoral Research Fellow – Innate Immunology

    Swiss Federal Institute of Technology in Lausanne – Lausanne, Switzerland

    Postdoctoral Fellow Position – B Cell Biology

    University of Toronto – Toronto, Ontario, Canada

    Postdoc/Research Scientist – Immunology

    H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States

    Research Fellow – RNA Biology

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Human Immunology News Twitter